Fig. 5
From: LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells
LOXL2 suppresses sensitivity in TNBC cells. a Cell viability was measured at different timepoints using an MTT assay of cultured different breast cancer cells and PDXs. The effects of doxorubicin, TSA, and doxorubicin plus TSA were analyzed. b Dissociated cells from PDX-549 were orthotopically implanted into NOD/SCID mice and injected intraperitoneally twice weekly with TSA (0.25 mg/kg), doxorubicin (2 mg/kg mouse weight), or doxorubicin plus TSA. Tumor volumes were measured twice a week and are given as averages. Results are given as averages of six independent tumors ± SEM
